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GENETIC TECHNOLOGY: LAW AND POLICY FOR THE
BRAVE NEW WORLD
HAROLD P. GREENt
During the past several years, developments in the biomedical sciences
relating to genetics have given rise to dramatic possibilities for human
intervention in the basic genetic processes.' Such intervention may be
directed towards the reduction or elimination of disease of genetic origin.2
It may be directed towards the gratification of parental desires for children
with predetermined biological characteristics. It may also be directed
towards the modification of the natural processes of evolution-a modifi-
cation of the basic characteristics of living creatures, including man. The
intervention may be through negative means such as abortion to eliminate
fetuses with undesirable characteristics or measures to discourage mar-
riages or child-bearing where defective children may result,3 or it may be
through positive means such as therapy or the encouragement of marriages
and child-bearing likely to produce desired results. There has been a com-
prehension on the part of the biomedical community that these develop-
ments will have a profound impact on society, and the biological com-
munity has undertaken to engage representatives of other disciplines-
t Professor of Law, The George Washington University National Law Center.
The author is a member of the Genetics Task Force of the Institute of Society, Ethics
and the Life Sciences. The work of that Task Force has been supported in part by a
National Institutes of Health grant (No. 1-RO-1-GM 19922-01). Although some of
the matters discussed in this article have been the subject of the Task Force's delibera-
tions, the views expressed herein are solely those of the author.
1. In order to enhance comprehensibility of this paper to its primary audience, no
effort has been made to describe the fundamental principles of genetics or the
scientific state of the relevant biomedical knowledge and techniques. The author has
attempted to describe the relevant scientific and technological matters simply, and free
of scientific jargon, based on his own exposure to these matters in the course of
various interdisciplinary projects. Indeed, the author readily concedes that he is in no
way expert in these matters; at the same time, he is convinced that lawyers and
others interested in the policy implications are fully capable of pursuing these questions
on the basis of articulated conclusions without any need for a comprehensive under-
standing of the underlying data. For a simple discussion of many of the basic scientific
principles see REPORT OF THE SCIENCE POLICY RESEARCH DivISiON, CONGRESsIONAL
RESEARcH SERVICE TO THE SUBCOMM. ON SCIENCE, RESEARCH, AND DEVELOPmENT OF
THE HOUSE COMM. ON SCIENCE AND AsTRONAuTICS, 92D CONG., 2D SEss., GENETIC
ENGINEERING, EVOLUTION OF A TECHNOLOGICAL ISSUE, (Comm. Print 1972) [hereinafter
cited as REPORT OF THE SCIENCE POLICY RESEARCH DmSION]; Vukowich, The Dawning
of the Brave New World-Legal, Ethical, and Social Issues of Eugenics, 1971 U.
ILL. L.F. 189 [hereinafter cited as Vukowich].
2. For estimates of the substantial costs to society of genetic disease see REPORT
OF THE SCIENCE POLICY RESEARCH DIVISION, supra note 1.
3. For a discussion of negative eugenics programs see Vukowich, supra note 1, at
214-31.
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philosophers, theologians, lawyers, ethicists, sociologists, etc.-in specula-
tions and discourse as to the social consequences of the use of the new
genetic knowledge. To this end, a major interdisciplinary conference was
held on this subject in October, 1971. The keynote address was delivered
by Dr. Tracy Sonneborn, an Indiana University geneticist. In this ad-
dress, Dr. Sonneborh identified three major categories of present and
potential use of genetic knowledge.4 The following discussion is based on
the three categories discussed by Dr. Sonneborn.
First, it is now technologically feasible to identify individuals who
are carriers of certain abnormal genes and chromosomes and therefore, as
parents, risk producing children with genetic disease.' In addition, it is
now feasible, through a procedure known as amniocentesis,6 to make a
positive identification of the actual presence of certain genetic conditions
in the fetus. These capabilities, which are expected to broaden to include
more such conditions and diseases, greatly expand the options available to
potential parents. An individual's knowledge that he in fact carries
abnormal genes or chromosomes can assist him in making sound deci-
sions as to marriage and procreation. Knowledge that a fetus will be born
with a serious genetic disease provides the parents with the option of
avoiding great misery and expense by electing to terminate the pregnancy
by abortion. Indeed, this latter capability can be used on an even broader
basis to terminate pregnancies where it is determined that the fetus will be
born with characteristics which are less than optimum from the standpoint
of the parents' desires. For example, it is presently possible reliably to
determine the sex of the fetus through amniocentesis, thereby enabling the
parents, theoretically at least, to elect abortion to prevent the birth of a
child of the "wrong" sex so that they can try again for the "right" sex.'
Although these techniques may be completely justifiable when used
to expand the options of individuals within the context of the physician-
patient relationship, more difficult questions are presented by use of
4. Sonneborn, Ethical Issues Arising From the Possible Uses of Genetic Knowl-
edge, in ErHCAL IssuEs IN HUMAN GENETIcs 1 (B. Hilton, D. Callahan, M. Harris,
P. Condliffe, & B. Berkley eds. 1973) [hereinafter cited as ETmCAL ISSUES].
5. This can be accomplished simply with a blood test.
6. A long needle is inserted into the abdomen of a pregnant woman in order to
withdraw a small quantity of amniotic fluid. Analysis of this fluid enables confirma-
tion or negation of the presence of a large number of genetic disorders in the fetus
with a very high degree of reliability. Experience to date suggests that amniocentesis
involves only minimal risk to either woman or fetus.
7. In December, 1972, the author presented a paper at the annual meeting of the
American Association for the Advancement of Science in which he stated that it
was now technically feasible for parents to choose the sex of a child. This was
given wide press coverage. The author thereafter received several letters from eager
women in Canada and the United States requesting information as to where they might
go to obtain information as to choosing the sex of their next child.
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these techniques on a mass basis. Numerous programs have been de-
veloped to bring the benefits of this new genetic knowledge to the public
at large through "genetic screening" to identify carriers of genetic condi-
tions in order to assist them in making use of the available options. A
number of states have, in fact, enacted legislation providing, and in some
cases requiring, genetic screening for sickle cell anemia.' The necessity
for and desirability of such statutory screening programs, and the con-
stitutionality of mandatory genetic screening statutes, are subject to ques-
tion. Beyond these questions, however, there are fundamental issues as to
how the information derived from genetic screening will be used.
Although it can be argued that a useful purpose is intrinsically served by
providing individuals with greater knowledge of their genetic character-
istics, this is by no means clear. Such knowledge, especially when it is not
actively solicited in the physician-patient relationship, can have a pro-
found, perhaps traumatic, effect on the individual. If, moreover, the in-
formation is communicated to third parties, this can be injurious to the
individual. Concern has been expressed that information developed in
screening for sickle cell anemia will be communicated to third parties
or to data banks with the result that the individual may be stigmatized
or that he may be denied insurance or employment on the basis of the
information.'
Particularly difficult questions are raised by the possibility that gene-
tic dossiers may be used by government for public health purposes. Exist-
ing statutes prohibiting consanguineous marriages or the marriage of
persons with various diseases or biological deficiencies may be broadened
to ban or regulate the marriage of persons with genetic characteristics in-
dicating a probability that any children born will be defective. The interest
of the state in preventing the birth of genetically defective children, and in
protecting future generations, may lead to laws mandating abortion to pre-
vent the birth of such children. Aside from such negative eugenics laws,
it is not difficult to visualize use of genetic dossiers by the state in positive
eugenics programs to improve the quality of the population. Development
of reliable data establishing a link between genetic characteristics and
aberrant or antisocial behavior could provide government with new
methods of minimizing crime and for identifying potential criminals for
purposes of special treatment."
The second potential use of the new genetic knowledge relates to in
8. For a discussion of these statutes see Powledge, The New Ghetto Hustle, 1
SAT. Rav. OF THE SCIENCcS, Feb., 1973, at 38 [hereinafter cited as Powledge].
9. See Lubs, Privacy and Genetic Information, in ETHICAL IssUEs, tispra note
4, at 267.
10. See notes 40 & 41 infra & text accompanying.
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vitro fertilization. It is now possible to extract human eggs from a woman
and to fertilize them in vitro.1 It is believed that scientists may attempt
in the near future" to implant such a fertilized egg in the uterus of the
woman from whom the eggs were obtained in the expectation that she
would then proceed to bear and give birth to a child in a normal manner.3
This technique, if perfected, is obviously beneficial, since it provides a
means whereby a woman who is otherwise incapable of having her eggs
fertilized in the normal manner could have children. On the other hand,
before the technique can be regarded as perfected, there will have to be
human experimentation, and in the process of experimentation, there
Will be a first child born as a result of in vitro fertilization and then a few
others will follow. What will be their fate in society as the first "test tube
babies," objects certainly of great scientific, if not public, curiosity? And
what is the morality, indeed the legality, of performance of this experi-
ment, even with informed consent of the mother, when there exists at
least the possibility that the experiment will produce a defective, deformed,
or monstrous child? What are the interests of such a potential child in
the performance vel non of the experiment which will bring him into this
world ?"4
The concept of in vitro fertilization involves a number of interesting
alternative scenarios. It will open the door to surrogate motherhood-to
wombs for rent. One can visualize the possibility that a woman may
undertake, for a fee, to have the fertilized egg of another woman implanted
in her womb in order that the donor of the egg may have her-and her
husband's-biological child without the burden of child-bearing. In the
eyes of the law, whose child will it be: the child of the donor of the egg
or the child of the surrogate who bears and delivers the child? And would
contracts for surrogate motherhood be legally enforcible? In another
scenario, the egg might be fertilized, with or without the knowedge and
11. Experiments have already been conducted in which eggs have been removed
from women, fertilized in vitro in a laboratory and grown in a laboratory culture to
the blastocyst stage, i.e., the stage reached in humans seven to eight days after ferti-
lization at which the early embryo normally implants itself in the uterine lining. Kass,
Babies by Means of It Vitro Fertilization: Unethical Experiments on the Unborn?,
285 N.E.J. MED. 1174 (1971) [hereinafter cited as Kass].
12. REPORT OF THE SCIENCE POLICY DIvisiox, supra note 1, at 18; Kass, supra
note 11.
13. This technique has been widely used in animal husbandry and has been tested
in laboratory animals to the point that the blastocyst of a mouse has been implanted in
the uterus of the mouse with full development and successful reproduction. REPORT OF
THE SCIENCE POLICY RESEARcH DIVlSloN, supra note 1, at 19.
14. For a discussion of the ethical and policy issues see Kass, siepra note 11;
Ramsey, Shall We "Reproduce"? The Medical Ethics of In Vitro Fertilization, 220
J.A.M.A. 1346 (1972); Ramsey, Shall We "Reproduce"f Rejoinders and Future
Forecast, 220 J.A.M.A. 1480 (1972).
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consent of the donor, for implantation in a woman who is a stranger to the
entire transaction. Or scientific researchers may use the fertilized egg for
experimentation to observe the processes of embryonic maturation or to
see how long it can be made to develop in vitro. At the end of the road,
perhaps, scientists may be able to maintain a fetus in vitro to the point of
"birth."
Closely related to in vitro fertilization is the possibility of cloning."
In cloning, the nucleus of the egg would be removed and replaced by a
nucleus obtained from a body cell of a particular individual. Theoretically
at least, this would result in the development of an individual who is bio-
logically identical to the individual who donated the nucleus, thus creating
the possibility of producing multiple biological carbon copies of any given
individual. For example, it might be possible through cloning to produce
ten, a hundred, or any number of biological carbon copies of a Willie
Mays, an Edward Teller, or a Moshe Dayan.
The third category of use of genetic knowledge relates to more
direct genetic surgery or other forms of genetic therapy. Such tech-
niques may be practiced to remedy disease or to eliminate defects
which may result in diseased offspring.' They may also be practiced
for reasons of positive eugenics, to improve the quality of children of
specific parents, or to improve generally the quality of future genera-
tions by further deliberate intervention in the processes of evolution.
Use of all of these technologies will have an obvious impact on vari-
ous traditional substantive areas of the law. For example, there will be
questions as to the legal duties and privileges arising in the doctor-patient
relationship; there will be questions as to privacy; some applications of
in vitro fertilization or cloning would raise substantial legal issues as to
parentage and relationships between individuals; and involvement of
government in the use of genetic knowledge and technologies would raise
constitutional questions. Problems such as these, with which the law will
eventually have to reckon are so unique that it would be idle speculation to
attempt to predict how the law will respond to these new stimuli. The
purpose of this paper, therefore, is not to explore the manner in which sub-
stantive law will be affected by the new genetic technology, but rather to
discuss the processes through which laws may evolve to govern its use.
A basic distinction must be drawn between two major categories of
use of genetic technology. The first category involves decisions which are
made by individuals on a voluntary basis. An individual has, or seeks,
knowledge as to what can be accomplished through use of genetic knowl-
15. REPORT OF T3, E SciExcE POLICY RESEARCH DIVISIo, supra note 1, at 21-22.
16. Id. at 26-28.
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edge and technology, and voluntarily, in conjunction with his physician or
other practitioner of genetic technology, submits to some form of treat-
ment. The second category involves the possibility that government will
decide to use the new genetic knowledge for purposes of the public health
or welfare. Such possibility might involve requirements or inducements
for genetic screening or treatment or the enactment of laws which in one
way or another may restrict the freedom of persons with specified genetic
conditions.
THE PRIVATE, VOLUNTARY USE OF GENETIC TECHNOLOGY
Heretofore, the concern of the law with biomedical science and tech-
nology has been focused primarily on the one-to-one relationship between
physician and patient and on the rights and obligations flowing from this
relationship. There has been very little effort at affirmative government
regulation of medical practice. This undoubtedly reflects the fact that
medicine is a self-regulating profession in which abuse is minimized
through the application of ethical principles and standards of peer review.
Accordingly, virtually all of the law relating to the physician-patient rela-
tionship is to be found in common law precedents. It is to be expected,
therefore, that the legal system will initially take cognizance of the new
genetic technology as the courts are called upon to decide cases brought
by patients who allege that they were in some way wronged by what the
genetics practitioner did or did not do. As such cases are decided, a body
of law directly pertinent to genetic technology will come into existence.
Accordingly, subject to legal principles which will evolve in time
through case-by-case decisions, physicians will use genetic knowledge as
they see fit, hopefully with informed consent of their patients, in the light
of their profession's ethical standards. In this connection, it should be
noted that use of genetic knowledge will represent a substantial expansion
of the traditional role of the physician. Traditionally, the physician's func-
tion has been to treat and cure his patient's disease. Increasingly in recent
years, there has been a recognition that the physician's function is also to
try to prevent his patient from developing disease. To a large extent, how-
ever, the physician's use of genetic technology is not directed towards the
treatment or prevention of disease in his patient, but rather to the treat-
ment or prevention of disease in the patient's future offspring. If such
future offspring is a fetus, it can be argued that the fetus is also the physi-
cian's patient, but there is a logical difficulty with this position where the
treatment or prevention of the disease involves killing the fetus by abor-
tion. More obviously, the physician can hardly be regarded as treating or
preventing disease when he employs procedures intended to enable parents
to produce a child of a chosen sex or with other desired biological char-
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acteristics. A major component of the use of genetic knowledge is, there-
fore, provision of a service which will make the patient happier or enhance
his sense of well-being. This extension of the physician's role is not a uni-
que phenomenon. Performance of "abortions on demand" or cosmetic
surgery, for example, may also be beyond the scope of the treatment or
prevention of disease. It remains to be seen whether the medical profession
will adopt any limitations on the purposes for which genetic technology
will be used.
It is, of course, possible that society may react to the use of genetic
technology through enactment of regulatory laws. This is not likely to
result, however, unless the medical profession itself fails to curtail practices
which society regards as abusive. On the other hand, even absent abuse,
one can visualize the possibility that the broad social consequences of in-
dividual decisions, in the aggregate, may warrant regulatory action. For
example, the use of genetic techniques giving parents the option to choose
the sex of their children could result in a serious imbalance of the ratio of
males to females in our society, with obvious social consequences. Govern-
ment may well have a legitimate interest in taking regulatory action to
prevent or correct this imbalance. And, although the recent Supreme Court
decisions on abortion suggest that the fetus is an expendable non-person,"7
there may be sufficient interest in preventing injury to a fetus to warrant
regulation of practices which may result in the birth of a defective child.
Similarly, if in vitro fertilization produces "wombs for rent" or surro-
gate child-bearers, there would be an obvious need for regulation. In
short, genetic intervention in individual cases would appear to involve, to
a greater extent than in the case of other medical procedures, important
societal interests. It is worth noting, if this societal interest is sufficient
to sustain regulation of actions flowing from decisions made in the
physician-patient relationship, that this would extend the long arm of
governmental authority into a new area of personal decisionmaking where
the need for intense privacy has heretofore been recognized.
In general, therefore, genetic intervention undertaken in the context
of the usual doctor-patient relationship will not result in any unique legal
questions. It would appear that the self-governing mechanisms of the
medical community can deal effectively with the new kinds of questions
that are presented. The courts will, of course, pass upon alleged wrongs
resulting from the physician's treatment of his patients, and the possibility
exists that affirmative regulation may be necessary if abuses or social prob-
lems appear.
On the other hand, the problem of genetic screening by private agen-
17. Doe v. Bolton, 93 S. Ct. 739 (1973) ; Roe v. Wade, 93 S. Ct. 705 (1973).
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cies on -a voluntary, consensual basis warrants special attention. Although
screening programs may be under the supervision of a physician, they do
not necessarily or usually involve the normal one-to-one relationship be-
tween physician and patient. Indeed, the person screened may never en-
counter a physician in the entire process of screening. The major purpose
of genetic screening is, of course, to develop information as to whether a
person who is screened is at risk of producing a child with genetic disease.
Three basic types of questions have been raised as to the legal relationships
between a screenee and the screening agency. First, what information
must the screening agency give to a candidate for screening in order to
meet the requirement for informed consent if, indeed, informed consent is
legally necessary? For example, must the subject be informed of the risk
of infection incident to the taking of blood? Must he be informed, before
screening, of the consequences if there is a positive finding? Must he be
informed that disclosure to him of a positive finding could have a sub-
stantial effect on the subsequent course of his life? Second, does the
screening agency have a duty to inform the screenee as to the results of the
screening? Must he be informed of negative findings? Will the screen-
ing agency be liable if it negligently fails to inform the screenee of a posi-
tive finding? May the screening agency deliberately withhold disclosure of
positive findings because, for example, it believes disclosure might be
psychologically devastating to the subject? Third, what duty does the
screening agency have to maintain the confidentiality of the results of
screening in individual cases? If the results of screening are positive, may
the screening agency pass on the information to relatives of the subject
who may be similarly affected? May it disclose the results to insurance
companies, employers, or government agencies? It is difficult to provide
reliable answers to any of these questions on the basis of presently existing
precedents, since all of the precedents arise in the context of the traditional
one-to-one physician-patient relationship which does not exist in genetic
screening programs. What can be said is that in the cases involving the
physician-patient relationship, there seems to be no suggestion that specific
informed consent is required in connection with relatively routine diag-
nostic proceedings ;8 no clear requirement for informing the patient as to
the diagonostic results, except perhaps in connection with a proposed
18. No decisions have been found imposing a requirement for informed consent in
connection with relatively simple diagnostic procedures such as blood tests. Such re-
quirement has been found primarily with respect to experimental procedures, therapeu-
tic procedures involving significant risk and in cases in which alternative courses of
treatment were available. E.g., Canterbury v. Spence, 464 F.2d 772 (D.C. Cir. 1972);
Cobbs v. Grant, 8 Cal. 3d 229, 502 P.2d 1, 104 Cal. Rptr. 505 (1972). Nevertheless, since
the need for informed consent is likely to be measured after the fact in the light of the
consequences giving rise to litigation, the prudent physician will make an effort to
disclose significant risk to the patient and obtain his explicit consent.
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course of treatment;9 and no absolute requirement for confidentiality of
the results of the diagnosis.2" It seems doubtful that more stringent re-
quirements would be found in areas not involving the special doctor-
patient relationship.
Genetic screening does, however, involve some additional considera-
tions. Informing a person that he is the carrier of genetic disease, and that
this situation cannot be corrected, may have a traumatic effect on him and
could alter the course of his future life. This traumatic effect can be ex-
acerbated if the information is disclosed to his family, his potential spouse,
employers, or insurance companies.2" It would seem desirable that dis-
closure of the information to the individual who has been screened be
coupled with adequate professional counseling services. This raises the
question whether some form of government regulation may be necessary
to ensure that genetic screening is conducted by responsible agencies, with
adequate professional staff, and with safeguards to minimize the possi-
bility of adverse consequences. At the very least, it would be desirable to
require that all genetic screening programs include a carefully thought out
statement, to be given to all potential screenees, articulating the policies of
the screening agency with respect to these matters. Such a statement
would in itself serve to define the legal rights and duties of the parties and
19. Most decisions imposing liability on a physician for withholding information
arise in situations in which the patient required the information in order to give his
informed consent to a proposed therapy. Even in such cases, the physician is privileged
to withhold information if he believes disclosure would be harmful to the patient.
Lester v. Aetna Casualty & Surety Co., 240 F.2d 676 (5th Cir. 1957); Natanson v.
Kline, 186 Kan. 393, 350 P.2d 1093 (1960) ; Hunt v. Bradshaw, 242 N.C. 517, 88 S.E.2d
762 (1955). On the other hand, it would appear, despite the lack of authority, that a
physician would be found negligent if he failed to disclose a treatable condition to his
patient where the patient sustained injury as a consequence of lack of treatment or
delayed treatment. This question seems, in any event, to be largely hypothetical in
relation to genetic screening programs since their very purpose is to inform the persons
screened of genetic abnormalities.
20. The legal duty of a physician to maintain information concerning his
patient in confidence is subject to a number of exceptions. He may disclose information
to governmental bodies as validly required by law. Davis v. Rodman, 147 Ark. 385,
227 S.W. 612 (1921); Skillings v. Allen, 143 Minn. 323, 173 N.W. 663 (1919). Dis-
closure to the patient's spouse is generally permissible. Pennison v. Provident Life &
Accident Ins. Co., 154 So. 2d 617 (La. App. 1963) ; Curry v. Corn, 52 Misc. 2d 1035,
277 N.Y.S.2d 470 (Sup. Ct. 1966). In Simonsen v. Swenson, 104 Neb. 224, 177 N.W.
831 (1920), it was held that a physician was not liable for informing a hotel in which
his patient was staying that the patient had a contagious disease. In Berry v. Moench,
8 Utah 2d 191, 331 P.2d 814 (1958), it was stated that a psychiatrist was privileged to
disclose to a prospective bride that his patient, the prospective groom, had a pyschiatric
disorder. Disclosures to other parties have likewise been upheld. Hague v. Williams,
37 N.J. 328, 181 A.2d 345 (1962) (disclosure to a life insurance company); Clark v.
Geraci, 29 Misc. 2d 791, 208 N.Y.S.2d 564 (Supp. Ct. 1960) (disclosure to an employer).
21. See M. Frankel, Genetic Technology: Promises and Problems, THE GEo.
WASH. U. PROGPAM OF POLICY STUDIES IN SCIENCE & TECHNOLOGY, MONOGRAPH No.
15, at 68-73 (1973).
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would avoid the vagaries of resolution under the present highly uncertain
common law principles.
USE OF GENETIC TECHNOLOGY BY GOVERNMENT
It is, of course, a legitimate function of government to promote and
protect the public health." To this end, government provides medical
facilities and personnel for the prevention and treatment of disease and
adopts various measures intended to prevent the spread of contagious and
infectious diseases. It is clearly within the power of government to iden-
tify persons with communicable diseases23 and to adopt measures to pre-
vent their communication.24 In these respects, the rights of individuals
must yield to the more substantial rights of society as a whole.25 Thus, for
example, it has been recognized that the government may require all per-
sons to be vaccinated for small pox even though some persons may be in-
jured by the vaccination.26 It is clear, moreover, that such powers of
government are not limited to those exercised for the protection of the
existing population. There is ample precedent for the proposition that the
public health powers of government may be exercised in order to protect
future generations from the spread of disease through genetic processes.27
A number of states have already taken cognizance of the new capa-
bilities of genetic science in enacting statutes providing or requiring
genetic screening with respect to sickle cell anemia. Sickle cell anemia is
a blood disorder which exists predominately in blacks. It is an autosomal
recessive condition, which means that it can be transmitted genetically only
if both parents are carriers of the sickle cell gene. In such cases, there is
one chance in four that any child of that couple will be born with the
disease. A child born with sickle cell anemia will almost always experience
excruciatingly painful "sickle cell crises" caused by blockages of the capil-
laries. There is no known cure for the disease, and most affected persons
die by the age of forty. Individuals who are carriers of the sickle cell
gene are described as having "sickle cell trait" and are under no substantial
disability except that symptoms of the disease may be experienced under
certain circumstances, e.g., at high altitudes.
22. Holden v. Hardy, 169 U.S. 366, 395 (1898). As stated in Roe v. Wade, 93
S. Ct. 705 (1973), "a state may properly assert important interests in safeguarding
health." Id. at 727.
23. Rock v. Carney, 216 Mich. 280, 185 N.W. 798 (1921).
24. See generally 39 Amr. JuR. 2D Health § 29 (1968).
25. Jacobson v. Massachusetts, 197 U.S. 11 (1905).
26. Id.
27. Buck v. Bell, 274 U.S. 200 (1927). The public health power of the states has
been described in the broadest possible terms as permitting enactment of "health laws
of every description" so long as it does not infringe constitutionally granted rights.
Jacobson v. Massachusetts, 197 U.S. 11, 25 (1905).
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Some of the states which have enacted legislation concerning sickle
cell anemia require screening of all persons for the trait and for the disease.
Screening is variously required under these statutes at birth, upon entry
into school, or as a prerequisite for a marriage license. "
The wisdom of and necessity for mandatory screening for sickle cell
anemia are open to serious question. Identification of sickle cell anemia at
any early age may enable ameliorative management of the diseased indivi-
dual, but no cure is available. Identification of the carriers of the sickle
cell gene at birth or upon entry into school would not appear to have any
useful purpose, since the information is really relevant only with respect to
decisions as to marriage and procreation. On the other hand, for a child
to be labeled as a sickle cell carrier could have an emotionally traumatic
effect on him and an adverse effect on his employability and insurability.
There are some who question the constitutionality of the mandatory
sickle cell screening statutes.29 It is argued, deductively, that mandatory
screening violates the right to privacy, particularly with respect to deci-
sions as to marriage and procreation, established in Griswold v. Connecti-
cut,"' Eisenstadt v. Baird,3 and the abortion decisions. 2 It is difficult to
see, however, how mandatory sickle cell screening is more objectionable
from the standpoint of privacy than pre-marital screening for venereal dis-
ease and prohibitions against marriage of close relatives and persons with
venereal or other diseases. It is argued also that mandatory genetic screen-
ing for sickle cell anemia is unconstitutional because it serves no useful
purpose.33 This argument is based on the distinction between contagious
and infectious diseases which may spread rapidly and affect entire popula-
tions, and genetic disease Which, although communicable vertically, af-
fects fewer people, and spreads much more slowly. It is based also on the
proposition that for some detectable genetic diseases, such as sickle cell
anemia, unlike other diseases within the scope of the public health power,
no cure is available. It seems clear, however, that screening for sickle cell
anemia is constitutionally defensible against these arguments. As pointed
out above,3 the welfare of future generations is a legitimate concern of
the government.3" Moreover, the absence of a cure is not decisive.
28. For a discussion of these statutes see Powledge, sipra note 8, at 38.
29. Such questions have, for example, been raised and intensively discussed at
meetings of the Genetic Task Force of the Institute of Society, Ethics and the Life
Sciences.
30. 381 U.S. 479 (1965).
31. 405 U.S. 438 (1972).
32. Doe v. Bolton, 93 S. Ct. 739 (1973) ; Roe v. Wade, 93 S. Ct. 705 (1973).
33. Such questions have, for example, been raised and intensively discussed at
meetings of the Genetics Task Force of the Institute of Society, Ethics and the Life
Sciences.
34. See Jacobson v. Massachusetts, 197 U.S. 11 (1905).
35. See, e.g., Perez v. Lippold, 32 Cal. 2d 711, 198 P.2d 17 (1948); State v.
Troutman, 50 Ida. 673, 299 P. 668 (1931); Beans v. Denny, 141 Ia. 52, 117 N.W.
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Government may have a legitimate interest in such screening if for no
other purpose than to reduce the number of children born with genetic
disease who might burden the public health resources of government."
There are, however, two bases on which the mandatory sickle cell
screening statutes may in fact be vulnerable to constitutional attack. First,
as noted, it is difficult to identify any legitimate governmental interest in
the screening of infants and children. Second, to the extent that these
screening programs are directed only towards the black population, either
by statutory language or by implementation of the statutes, it can be
argued with force that they violate the equal protection clause of the four-
teenth amendment. It is clear that a discriminatory burden imposed upon
a particular racial group is inherently suspect under the fourteenth amend-
ment, but may be justified in terms of a compelling governmental
interest.37 It is not clear, however, that absent invidious discrimination,
and with a reasonable basis, government may not constitutionally single
out a particular racial group for special benefits. Nor is it clear to what
extent mandatory sickle cell screening is a benefit or a burden.
The problem of sickle cell screening is illustrative of a broader prob-
lem related to the fact that some genetic diseases are present predomin-
ately in specific ethnic groups. For example, Tay-Sachs distase is found
almost exclusively in Jews of Eastern European origin, and Cooley's
anemia is found primarily in people of Mediterranean origin. If govern-
ment is to screen for carriers of these diseases, it is obviously uneconomical
to screen everyone. The new genetic capabilities, therefore, are suggestive
of the possibility that racial and ethnic backgrounds may be constitutionally
relevant and appropriate for purposes of classification for genetic screen-
ing.
The mandatory screening for genetic conditions is, however, only a
starting point. The ability to readily identify carriers of genetic disease
1091 (1908) ; Shackleford v. Hamilton, 93 Ky. 80, 19 S.W. 5 (1892) ; Ryder v. Ryder,
66 Vt. 158, 28 A. 1029 (1894); Grover v. Zook, 44 Wash. 351, 87 P. 638 (1906);
Peterson v. Widule, 157 Wis. 641, 147 N.W. 966 (1914).
36. Cf. State v. Acker, 26 Utah 2d 104, 485 P.2d 1038 (1971) (upholding a law
requiring motorcyclists to wear crash helmets); accord, Love v. Bell, 171 Colo. 27,
465 P.2d 118 (1970); Commonwealth v. Coffman, 453 S.W.2d 759 (Ky. 1970); State
v. Edwards, 287 Minn. 83, 177 N.W.2d 40 (1970); People v. Newhouse, 55 Misc. 2d
1064, 287 N.Y.S.2d 713 (Ithaca City Ct. 1968) ; State v. Anderson, 3 N.C. App. 124,
164 S.E.2d 48 (1968) ; State v. Craig, 19 Ohio App. 29, 249 N.E.2d 75 (1969) ; State v.
Lombardi, 104 R.I. 28, 241 A.2d 625 (1968); State v. Laitinen, 77 Wash. 2d 130, 459
P.2d 789 (1969). The fluoridation cases are also relevant. The courts have generally
upheld fluoridation measures, a form of compulsory medication, on the basis of general
benefit to the community. Chapman v. Shreveport, 225 La. 859, 74 So. 2d 142 (1954) ;
Readey v. St. Louis County Water Co., 352 S.W.2d 622 (Mo. 1966) ; Kraus v. Cleve-
land, 163 Ohio St. 559, 127 N.E.2d 609 (1955) ; Dowell v. Tulsa, 273 P.2d 859 (Okla.
1954).
37. Loving v. Virginia, 388 U.S. 1 (1967).
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may well be only a first step in public health measures to limit the spread
of such disease. The specific purpose of the mandatory sickle cell screening
statutes is not clearly articulated. They are, presumably, based on the pre-
mise that individuals who know they are carriers of the disease will at least
tend to take appropriate action to avoid giving birth to diseased children,
thereby tending to reduce the incidence of the disease in the population. It
is possible, however, that society will find the preventability of such
diseases to be so alluring that it will take further positive steps to ensure
that diseased children are not brought into the world. It is not difficult to
visualize the enactment of laws which will prohibit marriage of couples
who are definitely at risk of having children with specified genetic de-
fects.3" Nor is it difficult to visualize the enactment of laws requiring
amniocentesis to determine whether a fetus in fact will be born with gene-
tic disease. It would be a logical extension, although one involving obvi-
ous constitutional problems, to require abortion in the case of certain such
diseases which cannot be treated effectively and where the birth of the
child might impose substantial burdens of care on society."
There is also another troubling possibility with respect to govern-
ment's use of genetic screening or information gained through screening.
There presently is some evidence linking the XYY chromosomal abnor-
mality"0 with some forms of aberrant behavior." If this link should be
firmly established, or if other genetic conditions are clearly linked to anti-
social behavior, use of the information could be a highly useful tool in
dealing with the problem of crime. Restrictions could be placed on the
marriage of persons at risk of producing an XYY child; or, if the XYY
condition is diagnosed in a fetus, abortion might be made mandatory.
Alternatively, XYY boys might be subjected to special education designed
to minimize antisocial conduct, or they might be subject to special sur-
veillance, or to suspicion when police authorities are attempting to solve a
crime.
Beyond these considerations lurks the possibility that government
may seek to use genetic technology for purposes of positive eugenics, i.e.,
to upgrade the quality of the population. One can visualize, for example,
38. See Farrow & Juberg, Genetics and Laws Prohibiting Marriage in the
United States, 209 J.A.M.A. 534 (1969).
39. See Note, Eugenic Sterilization--A Scientific Analysis, 46 DENVER L.J. 631
(1969).
40. In a normal human being, there are two sex chromosomes. The sex chrom-
osomes are known as '-X" and "Y." The normal female has two "X" chromosomes
(X X), and the normal male has an "X" chromosome and a "Y" chromosome (XY).
In some cases, a male has an extra ", chromosome, and this is known as the "XYY
chromosome abnormality."
41. For a summary of present evidence with respect to this question see Hook,
Behavioral Implications of the Human XYY Genotype, 179 Sci. 139 (1973).
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that government at some future date might have an interest, for reasons of
national defense, national prestige, or public health, in using genetic tech-
niques to make people larger, smaller, healthier, brighter, calmer, etc.
Some suggest that such possibilities need not be of special concern
since, it is argued, government has long had it within its power to practice
positive eugenics on the basis of pre-existing knowledge by laws seeking to
maximize "good" marriages and minimizing "bad" marriages."' Recent
history teaches us, however, that government has a greater propensity to
deal with social problems through a technological "fix" than through a
wholly social "fix." For example, the availability of water fluoridation
technology has induced government to deal with the public health problem
of dental decay in children, although it has long had the capability to deal,
perhaps more effectively, with this problem through measures restricting
the manufacture and sale of candy and chewing gum. Automotive air pol-
lution is dealt with through incorporation of new gadgetry, rather than
through restrictions on automobile use. There is, therefore, a real possi-
bility that government will avail itself of the new genetic technology for the
betterment of society. This possibility is enhanced because of the reality of
international diversity. While American society may find the notion of
positive eugenics thoroughly repugnant, it is by no means clear that
other societies, those of China or the Soviet Union for example, will re-
frain from such practices. If another nation should embark upon a success-
ful program for upgrading its people so as to produce super-intellects,
super-soldiers, or even super-athletes, would it be possible for the United
States to stand idly by, watching, but not seeking to emulate these accom-
plishments?
DECISION-MAKING PROCESSES
Given the magnitude of the possible societal impact of the potential
use of genetic knowledge, it is certain that our society will be compelled to
make public policy decisions in this area, or at least to make decisions
as to whether or not such decisions should be made. Generally speaking,
there are four kinds of decisions which will be made with respect to use of
the technology.
At the most elementary level, decisions will be made by individuals.
Physicians will decide that something can be done in a particular case or
situation, and persons who want to have the service performed will decide
to have it done.
At the second level, the physician's decision to proceed or not to pro-
ceed, and the manner in which he does proceed, may be subject to deci-
42. See, e.g., J. MADDOX, THE DOOMSDAY SYNDR Om 9 (1972).
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sions made by the medical community relating to the standards prescribed
for the practice of medicine. These standards may be found in the ethical
codes of the medical associations, in the general consensus of the profes-
sion as to what is proper and improper, and in the standards and peer
review procedures of hospitals. Although such standards are not law, and
are not legally enforceable, departure from the standards may result in
professional sanctions and are relevant in determining a physician's liabi-
lity in the event a patient should bring suit. General standards of this kind
may also emerge from public or quasi-public bodies such as the National
Institutes of Health, the National Institute of Medicine, or the National
Academy of Sciences. Such pronouncements, although again not legally
enforceable, have great moral force. These private policy-making bodies
act as a buffer between the medical profession and the law. They deal
effectively with many issues which otherwise would become the subject
of resolution or regulation through formal legal processes. The buffer is,
however, not completely effective, since cases arising out of the physician-
patient relationship in fact frequently reach the courts.
At a third level, it is to be expected that legal standards relating to
the use of genetic knowledge will initially emerge in the courts as patients
who feel aggrieved, rightly or wrongly, about the consequences of the use
or nonuse of genetic technology in their cases seek legal remedy. The
first such cases will be decided by reference to precedents involving other
medical procedures. Eventually, however, a body of judge-made law
specifically applicable to genetic technology will evolve. What this body
of law will be cannot be predicted; nor can it be predicted whether or not it
will be deemed adequate for the protection of the various individual and
societal interests that are involved. The process of judicial law-making is
slow and uncertain. Law is made by the courts only in retrospect, with
respect to factual situations which arose months or years earlier. The
process of deciding today's cases by analogy to or distinction from the
precedents of the past frequently results in a period of trial and error before
sound law is made.
The fourth level of policy-making is that of legislation, the process of
conscious, deliberate articulation of standards which are intended for pro-
spective application. Generally speaking, legislatures are slow to enact
regulatory laws. Legislatures are busy and overworked. They have dif-
ficulty enough in dealing effectively with pressing immediate problems and
are reluctant to deal with problems which appear to be only hypothetical
and speculative. There is, moreover, sound justification for legislative
restraint, since premature regulation of technology may stifle progress
and cast the development of the technology in a mold which, in retrospect,
may be less than optimum. For these reasons, it is usually the case that
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regulatory laws are not enacted until the need is clearly demonstrated by
events; indeed, all too frequently regulation is not provided until long
after a crying need for it clearly exists. It simply cannot be expected,
therefore, that a legislature would in 1973 seriously consider legislation
relating to potential sexual imbalances in the population, the potential
problem of "wombs for hire" in in vitro fertilization or the potential prob-
lems incident to cloning.
If, therefore, the law follows its usual pattern of response to tech-
nology, it is likely that it will not begin to deal seriously with the problem
of controlling a particular use of genetic knowledge until after that use
has become a flourishing reality. At that stage, however, the problem of
enacting needed regulatory laws is complicated by the fact that important
vested interests in the use of the technology will have come into being. An
eager public will be clamoring for the immediate, personal benefits to them
with scant regard for the larger social issues which may be involved.
The basic problem is, of course, that the development and use of
genetic technology will, as in the case of other technologies, be incre-
mental. Genetic knowledge is derived from diverse sources such as cancer
research, botanical applications, and animal husbandry, all of which are
beneficial. The techniques, when successfully used in animal experimen-
tation, may become ripe for human application. When a human patient
appears who can benefit from the procedure, an experiment may be at-
tempted. If the experiment fails, it may be attempted in second or third
patients, perhaps with some improvement in technique based on knowl-
edge derived from the initial failures. If it produces the desired result, use
of the technique will be extended to other patients. The successful use
having been established, there is a precedent for the use of broader or new
techniques. At every stage, the potential or demonstrated benefits are
obvious and immediate with respect to the patients. Potential adverse
consequences, particularly to society as a whole, tend to be relatively
remote and speculative. Why, therefore, it is said, should we deprive
people of these immediate and obvious benefits because of a generalized
concern about adverse consequences? It is time enough to worry about
the adverse consequences when we know with certainty that they exist.
Even if adverse consequences become demonstrable, the case for regula-
tion is not clear. Then the exercise becomes one of balancing the benefits
against the adverse consequences. The fact of the matter is that it is very
difficult to turn off a technology, however adverse its consequences may
be, after its use has become established. Usually, the most that can be done
is to regulate its use as to attempt to minimize the adverse consequences
while avoiding any loss of its benefits.
It is unlikely, therefore, that society will prevent the emergence of
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any of the applications of the new genetic knowledge. The best that can
be hoped for is that as they emerge they will be wisely used. If this as-
sessment is correct, we are on the way to the "brave new world," and it is
useful to consider what that world will be. It will be a world in which
there would be far less disease and far fewer defective human beings, and,
consequently, far less of the human suffering and misery which is incident
to the existence of diseased or defective individuals. The use of genetic
technology for negative eugenic purposes will also reduce the prevalence of
other undesirable biological characteristics. Individuals will have knowl-
edge of their genetic characteristics, and will be able to choose mates with
desired genetic characteristics. Parents will have options to choose the sex
and other biological characteristics of their children. In many cases
parents will eschew the sexual component of reproduction in favor of being
"bred" so as to produce optimum children. Great men and women will
permit themselves to be perpetuated, in multiple copies, by offering the
nucleii of their body cells for use in cloning. Children will be born with-
out the traditional biological relationship to mother and father, and those
who are the product of cloning will have a complex and uncertain bio-
logical and legal relationship with their parents, their biologically identical
"sponsor," and their biologically identical fellow-clones who have different
parents. Scientists will perform laboratory experiments on surplus fetuses
or fetuses generated for the purpose of the experimentation, and babies will
be born in the laboratory without benefit of a mother. Scientists will en-
deavor to "upgrade" and "improve" the biological nature of man. This
effort may result in the creation of a new species of man, i.e., superman.
Conversely, scientists will create new species of subhuman animals by
"mating" man with baboons, dolphins, or dogs. If such creatures come
into existence, will they have a role or function in "society?" Will we
regard them more as man than as baboon, dolphin, or dog? Government
will be able, even if not necessarily tempted, to use genetic technology for
its own, hopefully beneficient, purposes.
Is such a world good or bad, desirable or undesirable? Do we move
towards this world with hope or with fear? These questions cannot be
answered except in terms of one's own system of values. On the other
hand, this brave new world which can be foreseen is so different from the
world we know, so much an intervention in the forces of nature, that
movement in that direction should be the result of conscious decision by
society itself and not the result of aggregative individual decisions made in
terms of individual wishes without regard for the ultimate social conse-
quences. There no doubt are many in our society who will view the brave
new world with utter distaste or even horror. If their view should prevail,
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what could be done to halt the seemingly inexorable march towards this
new world?
Our American society places a high premium on individual freedom
to think, to do research, and to create. The acquisition of increasing know-
ledge is regarded as beneficial per se. We have never attempted to restrict
the directions in which scientific research may proceed or the quantum of
effort which is directed towards any particular scientific goal. 3 The
absolute freedom to do research means that increasing scientific knowl-
edge will inevitably be translated into technological capability. Our basic
premise has been that science itself should be free and unregulated, and
that regulation, if needed, should be imposed only on the technological ap-
plications of scientific knowledge. But, as discussed above, there are im-
mense practical and political problems involved in dealing effectively with
new technologies which are introduced incrementally as a result of small,
individual decisions where benefits are always immediate and obvious
and where adverse consequences are remote and speculative. If, then, it is
true that what man can do he will do, that scientific advance leads in-
evitably to technological application, it would appear that the process can
be interrupted only if restrictions are imposed on the research itself.
Such restrictions are, however, intolerable in our present society and, of
course, would present serious constitutional problems.
The problem is greatly complicated by the role of government as the
principal sponsor of scientific research and development. Before World
War II, there was only nominal financial support for scientific research
from government sources. Scientists were impelled to do research in those
areas into which they were led by their own curiosity supported by what-
ever funds they could find. Since World War II, however, the federal
government has made a massive commitment to the financial support of
scientific research and development. Billions of dollars have been ex-
pended on scientific education, with a consequent enormous increase in
the number of scientific workers in the population, and on the funding of
specific research projects. As a result, most basic scientific research is
done today with federal funding, and scientific resources are drawn into
43. It should be noted, however, that the availability of funds for the support of
scientific research and development may have a powerful influence on the scientific goals
which are pursued by individual investigators. Thus, for example, if the federal
government makes substantial funds available for research and development of therapies
for genetic disease and does not support research and development on techniques for
preventing such disease, there will be a strong tendency for diversion of scientific effort
towards the former and away from the latter. Indeed, the scientific community has
become so accustomed to reliance on public funding that it has been suggested that
a decision to abandon support of a particular line of research and development con-
stitutes a "suppression" of that technology. See Dyson, Death of a Project, 149 ScL
141 (1965).
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those areas of research in which federal funding is available. This massive
federal support has some important implications. The time scale for the
sequence of events from initiation of basic research to introduction of re-
sulting technology has been dramatically compressed, causing a tremend-
ous acceleration in the rate of scientific and technological advance. In
addition, the role of government as sponsor of scientific research and de-
velopment has an inevitable tendency to lead to government's promoting
the use of the resulting technology. In the very nature of the political
and bureaucratic processes, it is obvious that government officials will be
reluctant to be cast in the position of having spent millions of dollars on
research which serves no useful purpose. Thus, where the National In-
stitutes of Health provide substantial funding for a particular area of re-
search relating to "health," there are powerful pressures to see that the
results are in fact used for "health." Similar interests and pressures exist
with respect to the congressional sponsors of such research funding. When
a resulting technology is ripe for application, the governmental sponsors
adopt a classic form of advocacy: (1) use of the technology involves
obvious and substantial benefits to the public health; (2) although there
may be adverse consequences, we do not know this with certainty except
in the light of experience with its use; (3) if experience demonstrates that
there are adverse consequences, we may be able to eliminate or ameliorate
the adverse effects through some other technological "fix;" (4) if the ad-
verse consequences remain, we can enact regulatory laws which will enable
us to benefit from the technology while appropriately minimizing the ad-
verse effects; and (5) if all else fails, we can, of course, stop the use of the
technology. It would appear to be axiomatic, therefore, that government
sponsorship of a technology increases the inevitability that it will, in fact,
be used, since the government's vested interest causes it to act more as
promoter than regulator.
The enormous advances in genetic science and technology in the
United States have occurred in large part because of government financial
support. Although both the government sponsors and the scientists whose
work has been sponsored are fully aware of the important ethical and policy
issues that exist with respect to future use of the knowledge derived from
the sponsored activities, these issues have not surfaced in the decision-
making processes relating to government support of the research. The
general tendency has been to confine discussion of these problems within
small groups of elite experts in the relevant scientific disciplines and, oc-
casionally, to seek to involve broader elite groups, including experts from
other disciplines, in these speculations. No effort has been made to engage
the public generally in consideration of the ultimate potential implications
of the use of knowledge which will be derived from the research the public
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is presently being asked to fund. To do so might, of course, confuse and
alarm the public unnecessarily, because we don't know yet what is or is not
possible, and the potential implications are entirely speculative. Thus to
involve the scientifically uneducated public in a debate about the possible
brave new world of the future could result in a foolish negative reaction
leading to public policy decisions to curtail or terminate these highly bene-
ficial research programs.
The present system, therefore, involves the accelerated inevitability
that the new genetic technologies will become ripe for use and that they
will in fact be used, at least for a time. The decisions to proceed on this
course are made by small elite groups and are submitted to Congress, for
ratification in the appropriations process, without exposition of the basic
long-term policy issues. This system reflects a fundamental deficiency in
the democratic process. The decisions made today on support of genetics
research will shape tomorrow's world, and the public is entitled to partici-
pate fully in consideration of today's public policy decisions which may
represent a virtually binding commitment as to what the future conditions
of society will be. This is not to say that the brave new world will emerge
only as a consequence of federal funding. No doubt it will come, although
at a considerably later date, even if there is no government support at
all. In either event, whether the technology comes into being as a result of
small, incremental, individual decisions, or more rapidly through govern-
ment sponsorship, it is undeniably true that in a democratic society the
public, acting through responsive legislatures, should have the maximum
opportunity to shape the society in which it, and future generations, will
live.
A major difficulty standing in the path of effective public participa-
tion is the problem of the "two cultures."4 Scientists are dedicated to the
relentless pursuit of truth. They are intolerant of the political processes
in which ignorance, emotion, and bias so often shape public policy deci-
sions that are not consistent with truth. They fear the possibility, if scien-
tific matters are opened to public debate, that "wrong" decisions will be
made: that beneficial projects will be terminated, that public funds will
be expended on less than optimum programs, and, to some extent, that
their own sources of government funding will be curtailed, thereby de-
priving them of the opportunity to perform their good works. Scientists
tend to think, accordingly, that the solutions to these problems lie in better
scientific education of the public, in electing more scientists to legislative
44. The notion of "two cultures" originated in C.P. SNow, THE Two CuLTUREs
AND THE SCIENTIFIC REVOLUTION (1959). The two cultures discussed by Snow are
characterized by him as the "literary intellectuals" and the "scientists," and he discussed
the difficulties in communication between these two groups.
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bodies, or in entrusting decisions on scientific questions to scientific bodies.
But science is not a special, sacrosanct category in our society. It is
no more esoteric or worthy of protection than economics, sociology, agri-
culture, or law. We are accustomed in our society to maldng public policy
decisions in these areas on the basis of bruising political debate involving
frequent error and falsehood, and to the inevitability that "right" decisions
are commonly not made. If our society wanted to ensure that "right" deci-
sions are always made, it would not be dedicated to the democratic process.
There is, therefore, no reason why we should proceed on the assumption
that our decisionmaking mechanisms for questions of science policy must
be constructed to produce "right" decisions. Science, after all, speaks
with a strong and prestigious voice and has ready access to the press and
other forms of political communication. It has the ability to defend truth
vigorously and to. seek to correct "wrong" decisions if they are made.
It is to be hoped, therefore, that those who are presently serving as
the midwives for the emergence of the new genetic technology will re-
cognize a public responsibility to tell the public fully, candidly, and in
language the public can understand, where the new knowledge in genetics
may take us as this knowledge is expanded and used. The benefits should
be fully articulated because they are important; and the potential adverse
consequences of use, whether or not it is believed there will be use, should
be discussed with equal force. Only then will the democratic process be
able to produce decisions which reflect the values of our society. It is more
important that decisions be made in this manner than that "right" deci-
sions be made. It is possible, of course, that the forces already in motion
cannot be checked, but it is possible that they can be retarded, and this may
be advantageous in giving society more time to reflect upon, and adjust to,
what may be the inevitability of the brave new world.
It is not, of course, suggested that public policy decisions with respect
to genetic technology be made without the inputs of the scientific com-
munity. As Sir Harold Himsworth has noted, scientifically based matters
of political importance are never concerned with established knowledge,
but only with fields where possibilities and opportunities have been opened
but not yet established.4 It is important that the questions thus raised be
assessed by expert bodies not afflicted with excessive, often self-serving,
enthusiasms. The conclusions reached by such expert bodies are of the
utmost importance in the process of public policy decisionmaking. Of
greater importance, however, is that their conclusions not be accepted
ex cathedra as binding on the policy-makers. Their conclusions in them-
45. Himsworth, The Human Right to Life: Its Nature and Origin, in ETHiCAL
IssuEs, supra note 4, at 169.
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selves, and the processes through which these conclusions are reached,
involve substantial value judgments. The intermediate value judgments,
as well as the ultimate conclusions, should be subject to broad public
scrutiny and debate.
Finally, it is important to note the significance of genetic technology
at the international level. As Dr. Robert L. Sinsheimer has observed:
"One of the greatest threats to the rational development of genetic modi-
fication will appear if it should become captive to irrational, nationalist
purposes."4 A "genetics race" could have even more dangerous conse-
quences than an "arms race." It is imperative that steps be taken to estab-
lish some form of international controls in this area.
46. Sinsheimer, Prospects for Fiuture Scientific Developments: Ambuesh or Op-
portunity, in ETiICAL IssuEs, supra note 4, at 349.
